Isogenix is a precision medicine company developing therapies that target protein isoforms to treat neuromuscular and neurological diseases. The company's proprietary approach focuses on identifying and harnessing specific isoform variants to restore function in conditions like spinal and bulbar muscular atrophy. Their research combines advanced RNA-based medicine and gene regulation technologies to create targeted treatments for these challenging disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Neuromuscular and neurological diseases such as spinal and bulbar muscular atrophy and Duchenne muscular dystrophy lack targeted therapies that address the underlying molecular mechanisms. Current treatment approaches often fail to account for the complex roles of protein isoforms, which are alternative versions of proteins that can have distinct or even opposing functions in disease pathology. This gap limits therapeutic precision and patient outcomes.
Solution
Isogenix is developing precision therapies that harness the therapeutic potential of protein isoforms, with an initial focus on neuromuscular and neurological diseases. The company uses a proprietary approach combining cutting-edge research in RNA biology, gene regulation, and therapeutic genomics to identify novel genetic targets. By understanding how dysregulation of transcription factor dynamics, gene isoforms, and epigenetic regulation leads to disease, Isogenix designs therapies that restore normal function. Their work builds on advanced antisense oligonucleotide technologies and novel drug delivery systems, including peptide and exosome-based approaches, to create targeted treatments for these challenging conditions.
Target Audience
Primary customers are patients with neuromuscular and neurological diseases, as well as clinical partners and research institutions seeking advanced therapeutic options for conditions like spinal and bulbar muscular atrophy and Duchenne muscular dystrophy.
Features
- Proprietary platform for identifying and developing therapies targeting disease-relevant protein isoforms
- Advanced antisense oligonucleotide design for RNA-based precision medicines
- Novel drug delivery systems including peptide and exosome-based technologies
- Expertise in gene regulation and therapeutic genomics for target discovery
- Focus on genetic motor unit disorders including spinal and bulbar muscular atrophy
- Research capabilities spanning transcription factor dynamics and epigenetic regulation